<DOC>
	<DOC>NCT01531309</DOC>
	<brief_summary>Agomelatine (AGO178) was developed for the treatment of depression. A new formulation is being tested in the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet). The goal of this trial is to study the pharmacokinetics of agomelatine given as sublingual tablet in patients with liver impairment and to compare the results to those of healthy volunteers who receive the same treatment.</brief_summary>
	<brief_title>Pharmacokinetics of Agomelatine in Patients With Liver Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Patients with liver disease confirmed within 3 months of screening If liver impairment is caused by alcohol use, patients must have abstained from alcohol use within 3 months of study start Patients must satisfy criteria for Child Pugh Class A or B Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer Pregnant or nursing (lactating) women Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless using effective contraception during the study Donation or loss of 400 mL or more of blood within eight (8) weeks prior to initial dosing Significant illness within the two weeks prior to the dosing Patients with ChildPugh alterations due to a nonliver disease (e.g. cancer or treatment related weight loss). Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Liver impairment</keyword>
	<keyword>Major Depression Disorder</keyword>
	<keyword>Sublingual tablet</keyword>
</DOC>